The substantially increased level of growth hormones which were directly secreted to the circulatory system targeted more somatic cells triggering more cell division, protein synthesis, and bone growth (Mader, 2001). Thus, in a span of 10 years, Jessica gained 325 pounds in weight, and 7 inches in height which is and indication of increased metabolism.
3. At age 23 Jessica manifested suffering from intensifying migraines; impaired working ability as always tired, no menstrual cycle for 19 months; enlarge feet from size 9, 3 years back. At age 30 or 10 years after, Jessica gained 325 pounds in weight, and 7 inches in height. These clinical indicators support the diagnosis that indeed Jessica is suffering from acromegaly in as much as the symptoms are consistent with the indicators for the disease supposed by Dr Cook et al in 2004.
4. In case the clinical diagnosis is correct, then, biochemical GH level at 75g glucose test would be at1ng/ml to 100 ng/ml level (Cook et al, 2004). Obviously, this diagnosis is for a secondary disorder, which is adenomatous anterior pituitary gland or anterior pituitary gland tumor, where mass of the anterior pituitary gland could be equated to hypersecretory activities.
5. A 75g glucose test which is a biochemical test could confirm the clinical diagnosis. ...
Obviously, this diagnosis is for a secondary disorder, which is adenomatous anterior pituitary gland or anterior pituitary gland tumor, where mass of the anterior pituitary gland could be equated to hypersecretory activities.
5. A 75g glucose test which is a biochemical test could confirm the clinical diagnosis. 75g glucose can be administered orally to Jessica. Her GH levels can be monitored thereafter. This must be at intervals 0, 30, 60, 90, and 120 minutes. A GH reading at or between 1ng/ml to 100 ng/ml levels of IGF-I is indicative of acromegaly. This can be substantiated by the initial serum test for IGF-I levels (Cook et al, 2004).
6. In order to alleviate Jessica's acromegaly symptoms, Cook et al in 2004 suggested that the patient may be given a medical therapy consisting of somatostatin. Somatostatin may be introduced subcutaneously 3 times a day or every 8 hours. Somatostatin has been found to be capable of lowering the GH level of patients, as well as IGF-I levels in approximately 50 % to 70 % of recipients. The rate of normalization has been found to be within the region of 41 % to 67 %. However, the highest level of inhibition may be observed or experienced by Jessica after 2 hours. This level of inhibition will end in about 6 hours only (Cook et al, 2004). Nonetheless, in case Jessica will be found to be a good surgical candidate, then, surgery can be an option.
In the event that Jessica agrees to undergo surgery, the operation will then offer her a spin towards her normal GH secretions and IGF-I levels. This will also mean purging the mass end product and troubles linked to her neurons like migraines. Likewise, this will preclude recurrence of the tumor (Cook, 2004).